Evaluating bempedoic acid for the treatment of hyperlipidaemia

Penson, Peter E.; McGowan, Mary P.; Banach, Maciej

doi:10.1080/13543784.2017.1280458

Cited by 45 publications

(26 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bempedoic acid (ETC-1002) has a unique mechanism of action (adenosine triphosphate-citrate lyase inhibition) [ 71 , 72 ]. The efficacy of combination therapy with statins and bempedoic acid has been evaluated in a randomized controlled trial (NCT02072161) [ 73 ].…”

Section: Methodsmentioning

confidence: 99%

Management of Statin Intolerance in 2018: Still More Questions Than Answers

Tóth

Patti

Giglio

et al. 2018

Am J Cardiovasc Drugs

Self Cite

151

111

View full text Add to dashboard Cite

Statin therapy is generally well tolerated and very effective in the prevention and treatment of cardiovascular disease, regardless of cholesterol levels; however, it can be associated with various adverse events (myalgia, myopathy, rhabdomyolysis, and diabetes mellitus, among others). Patients frequently discontinue statin therapy without medical advice because of perceived side effects and consequently increase their risk for cardiovascular events. In patients with statin intolerance, it may be advisable to change the dose, switch to a different statin, or try an alternate-day regimen. If intolerance is associated with all statins—even at the lowest dose—non-statin drugs and certain nutraceuticals can be considered. This review focuses on the definition of statin intolerance and on the development of clinical and therapeutic strategies for its management, including emerging alternative therapies.

show abstract

Section: Methodsmentioning

confidence: 99%

Management of Statin Intolerance in 2018: Still More Questions Than Answers

Tóth

Patti

Giglio

et al. 2018

Am J Cardiovasc Drugs

Self Cite

151

111

View full text Add to dashboard Cite

show abstract

“…In a phase 2 trial, a synthetic small interfering RNA directed against PCSK9 was shown both to reduce PCSK9 and LDL-C levels [ 153 ]. Additionally, another novel agent, bempedoic acid, inhibits ATP citrate lyase (ACL), an enzyme involved in fatty acid and cholesterol synthesis, predominantly in the liver and white adipose tissue and has been shown to reduce LDL-C in several phase 2 trials [ 154 ].…”

Section: Lipid Modification Therapymentioning

confidence: 99%

Hypercholesterolaemia – practical information for non-specialists

Soran¹,

Adam²,

Mohammad³

et al. 2018

aoms

Self Cite

View full text Add to dashboard Cite

Hypercholesterolaemia is amongst the most common conditions encountered in the medical profession. It remains one of the key modifiable cardiovascular risk factors and there have been recent advances in the risk stratification methods and treatment options available. In this review, we provide a background into hypercholesterolaemia for non-specialists and consider the merits of the different risk assessment tools available. We also provide detailed considerations as to: i) when to start treatment, ii) what targets to aim for and iii) the role of low density lipoprotein cholesterol.

show abstract

“…The promising LDL-lowering effects of ETC-1002 from phase II trials remain to be confirmed by a phase III programme assessing its efficacy, safety and long-term outcomes (Bilen and Ballantyne, 2016 ). Since this agent has been also found to reduce C-reactive protein levels, better CVD outcomes may be possible through its implication in pro-inflammation processes (Penson et al, 2017 ).…”

Section: Management Of Fhmentioning

confidence: 99%

Familial Hypercholesterolemia: New Horizons for Diagnosis and Effective Management

et al. 2018

View full text Add to dashboard Cite

Familial hypercholesterolemia (FH) is a common genetic cause of premature cardiovascular disease (CVD). The reported prevalence rates for both heterozygous FH (HeFH) and homozygous FH (HoFH) vary significantly, and this can be attributed, at least in part, to the variable diagnostic criteria used across different populations. Due to lack of consistent data, new global registries and unified guidelines are being formed, which are expected to advance current knowledge and improve the care of FH patients. This review presents a comprehensive overview of the pathophysiology, epidemiology, manifestations, and pharmacological treatment of FH, whilst summarizing the up-to-date relevant recommendations and guidelines. Ongoing research in FH seems promising and novel therapies are expected to be introduced in clinical practice in order to compliment or even substitute current treatment options, aiming for better lipid-lowering effects, fewer side effects, and improved clinical outcomes.

show abstract

Evaluating bempedoic acid for the treatment of hyperlipidaemia

Cited by 45 publications

References 41 publications

Management of Statin Intolerance in 2018: Still More Questions Than Answers

Management of Statin Intolerance in 2018: Still More Questions Than Answers

Hypercholesterolaemia – practical information for non-specialists

Familial Hypercholesterolemia: New Horizons for Diagnosis and Effective Management

Contact Info

Product

Resources

About